title: No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
abstract: OBJECTIVE
  To determine prospectively intermediate-term toxicity and quality of life (QoL) of prostate cancer patients after intensity-modulated radiotherapy (IMRT).
  
  
  METHODS
  Fifty-five patients with localized prostate adenocarcinoma were treated by IMRT (76 Gy). Physicians scored acute and late toxicity using the Common Terminology Criteria for Adverse Events version 3.0. Patients assessed general and prostate-specific QoL before IMRT (baseline) and at 2, 6, and 18 months using European Organization for Research and Treatment of Cancer questionnaires QLQ-C30(+3) and QLQ-PR25.
  
  
  RESULTS
  Median age was 73 years (range, 54-80 years). Risk categories were 18% low risk, 60% intermediate risk, and 22% high risk; 45% of patients received hormonal therapy (median duration, 6 months). The incidence of urinary and bowel toxicity immediately after IMRT was, respectively, 38% and 13% (Grade 2) and 2% and none (Grade 3); at 18 months it was 15% and 11% (Grade 2) and none (Grade 3). Significant worsening of QoL was reported at 2 months with regard to fatigue (+11.31, p = 1.10(-7)), urinary symptoms (+9.07, p = 3.10(-11)), dyspnea (+7.27, p = 0.008), and emotional (-7.02, p = 0.002), social (-6.36, p = 0.003), cognitive (-4.85, p = 0.004), and physical (-3.39, p = 0.007) functioning. Only fatigue (+5.86, p = 0.003) and urinary symptoms (+5.86, p = 0.0004) had not improved by 6 months. By 18 months all QoL scores except those for dyspnea (+8.02, p = 0.01) and treatment-related symptoms (+4.24, p = 0.01) had returned to baseline. These adverse effects were exacerbated by hormonal therapy.
  
  
  CONCLUSIONS
  High-dose IMRT with accurate positioning induces only a temporary worsening of QoL.
authors.affiliation: Department of Radiotherapy, Centre René Gauducheau, Saint-Herblain, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Marchand
authors.forename: Sylvain
authors.initials: S
authors.lastname: Bourdin
authors.forename: Christelle
authors.initials: C
authors.lastname: Charbonnel
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Rio
authors.forename: Camille
authors.initials: C
authors.lastname: Munos
authors.forename: Loïc
authors.initials: L
authors.lastname: Campion
authors.forename: Angélique
authors.initials: A
authors.lastname: Bonnaud-Antignac
authors.forename: Albert
authors.initials: A
authors.lastname: Lisbona
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Mahé
authors.forename: Stéphane
authors.initials: S
authors.lastname: Supiot
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D011788:Quality of Life; D011832:Radiation Injuries / Q000473:pathology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*
chemical_list: D000726:Androgen Antagonists